

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: Algernon Pharmaceuticals Inc. (the “**Issuer**” or the “**Company**”).

Trading Symbol: AGN

Number of Outstanding Listed Securities: 135,732,455

Date: August 7, 2020

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Company has begun its Phase 2 clinical trial for IPF and chronic cough announcing its first patient dosed on August 5, 2020.**

**The Company has also begun its multinational Phase 2b/3 clinical trial for IPF and chronic cough having announced its first patient enrolled on August 5, 2020.**

**The Company is also supporting an investigator-led study of Ifenprodil in a COVID-19 Phase 2 in South Korea. The study has received ethics and regulatory approval.**

2. Provide a general overview and discussion of the activities of management.

**On July 07, 2020, the Company announced that it has begun screening patients for suitability for enrolment in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).**

**On July 16, 2020 the Company announced that it has completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for COVID-19. The principal investigator is Dr. Aimee Gonzalez, MD.**

**On August 05, 2020 the Company announced that the first patient has been dosed in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).**

**On August 05, 2020 the Company announced that it has enrolled its first patient in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The countries participating in the study include the U.S., Australia, Romania and the Philippines.**

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None**

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None**

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None**

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the dispositions was to a Related Person of the Issuer and provide details of the relationship.

**None.**

7. Describe the acquisition of new customers or loss of customers.

**None.**

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None**

9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

**None**

10. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

13. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds</b>
Common Shares	5,624,900	Issued 5,624,900 common shares as a result of 5,624,900 warrants with an exercise price of \$0.12 being exercised for proceeds of \$674,988.	For general corporate purposes.
Common Shares and Warrants	164,950	Issued 164,950 common shares and 164,950 warrants as result of 164,950 finders' warrants with an exercise price of \$0.085 being exercised for proceeds of \$14,020.75.  Each finders' warrant entitled the holder to purchase a common share and warrant for \$0.085. The warrant may be exercised for \$0.12.	For general corporate purposes.

14. Provide details of any loans to or by Related Persons.

**None.**

15. Provide details of any changes in directors, officers or committee members.

**None.**

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. Please to the "Risks Related To The Business" section of the Issuer's management discussion and analysis for the year ended August 31, 2019, which is available on SEDAR at [www.sedar.com](http://www.sedar.com).**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: August 7, 2020

Christopher Moreau  
Name of Director or Senior  
Officer

“Christopher Moreau”  
Signature

CEO  
Official Capacity

<b>Issuer Details</b> Name of Issuer	For Month End	Date of Report YY/MM/D
Algernon Pharmaceuticals Inc.	July 31, 2020	2020/08/07
Issuer Address Suite 915 – 700 West Pender Street		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 1G8	NA	(604) 646-1553
Contact Name	Contact Position	Contact Telephone No.
Christopher J. Moreau	CEO	(604) 398-4175 ext. 701
Contact Email Address	Web Site Address	
info@algernonpharmaceuticals.com	https://algernonpharmaceuticals.com/	